Phreesia (NYSE:PHR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Posted by Donald Scott on May 28th, 2026

Phreesia (NYSE:PHR – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03, FiscalAI reports. Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The business had revenue of $130.94 million for the quarter, compared to analysts’ expectations of $130.08 million. During the same quarter in the previous year, the business posted ($0.07) EPS. Phreesia’s revenue for the quarter was up 12.9% on a year-over-year basis.

Here are the key takeaways from Phreesia’s conference call:

Revenue rose 13% year over year to $130.9 million, driven by strong payment solutions growth of 40% and network solutions growth of 15%. The company also delivered its third straight quarter of positive net income and improved Adjusted EBITDA to $30.5 million.
Cash generation improved meaningfully, with operating cash flow of $23.9 million and free cash flow of $16.4 million, both up significantly from a year ago. Phreesia also refinanced its bridge loan into a new 5-year revolving credit facility, improving balance sheet flexibility.
AccessOne is becoming a larger growth driver after Phreesia expanded the PNC securitization facility to $300 million and extended it through April 2029. Management said this should broaden the addressable market, especially for non-investment-grade clients, but it was early to quantify the incremental opportunity.
The company kept fiscal 2027 guidance unchanged, maintaining revenue of $510 million to $520 million and Adjusted EBITDA of $125 million to $135 million. Management noted more variability in network solutions forecasting in the second half of the year, but said the rest of the business remains in line with March expectations.
Phreesia sees growth runway beyond PatientConnect from new products like ProviderConnect and continued AI-driven efficiency gains. Management said ProviderConnect already has momentum and is expected to contribute more in future years, while a May restructuring plan should deliver annualized expense savings.

Phreesia Stock Up 2.2%

NYSE:PHR opened at $9.15 on Thursday. The firm has a market capitalization of $565.01 million, a price-to-earnings ratio of 304.90 and a beta of 0.89. Phreesia has a twelve month low of $7.77 and a twelve month high of $32.76. The stock’s 50 day moving average price is $9.53 and its two-hundred day moving average price is $13.69. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.41.

Insider Buying and Selling

In other Phreesia news, insider David Linetsky sold 8,332 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $8.07, for a total transaction of $67,239.24. Following the transaction, the insider owned 224,056 shares of the company’s stock, valued at $1,808,131.92. The trade was a 3.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Allison C. Hoffman sold 14,483 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $8.07, for a total value of $116,877.81. Following the transaction, the general counsel directly owned 163,485 shares in the company, valued at $1,319,323.95. This trade represents a 8.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 50,493 shares of company stock worth $461,983 over the last 90 days. Company insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PHR. Royal Bank of Canada increased its position in shares of Phreesia by 208.8% during the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after purchasing an additional 16,309 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Phreesia by 471.2% during the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after acquiring an additional 132,015 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after acquiring an additional 2,158 shares during the period. NewEdge Advisors LLC boosted its stake in shares of Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after acquiring an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after acquiring an additional 2,402 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Stephens cut their price objective on Phreesia from $32.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 31st. Mizuho dropped their target price on Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 24th. Wells Fargo & Company reissued an “equal weight” rating and issued a $9.00 target price (down from $15.00) on shares of Phreesia in a research report on Wednesday, May 20th. Robert W. Baird reissued a “neutral” rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Finally, BMO Capital Markets dropped their target price on Phreesia from $32.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Phreesia currently has a consensus rating of “Hold” and an average price target of $19.06.

Get Our Latest Stock Report on PHR

Phreesia News Summary

Here are the key news stories impacting Phreesia this week:

Positive Sentiment: Phreesia reported first-quarter fiscal 2027 earnings of $0.05 per share, beating the $0.02 consensus estimate, while revenue of $130.94 million also topped expectations. Revenue grew 12.9% year over year, suggesting the business is still expanding. Phreesia Announces First Quarter Fiscal 2027 Results
Positive Sentiment: Management outlined FY2027 revenue guidance of $510 million to $520 million and said it expects adjusted EBITDA of $125 million to $135 million, which signals continued confidence in operating performance and profitability. Phreesia outlines FY2027 revenue of $510M-$520M while maintaining adjusted EBITDA of $125M-$135M
Neutral Sentiment: Several market recap and transcript articles are highlighting the earnings call, but they mostly restate the same quarterly results and do not appear to add materially new information for investors. Phreesia, Inc. (PHR) Q1 2027 Earnings Call Transcript
Neutral Sentiment: Multiple law firms issued reminders and lead-plaintiff notices tied to an already filed shareholder class action covering purchases from May 8, 2025 through March 30, 2026, with a July 13, 2026 deadline. These updates are procedural, but they keep litigation risk in focus. PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Negative Sentiment: The class action alleges Phreesia and certain executives made false or misleading statements about its long-term growth outlook, including risks tied to slowing growth in the Network Solutions segment and other concealed business weaknesses. That kind of litigation headline can weigh on investor confidence. PHR INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Phreesia, Inc. Investors

About Phreesia

(Get Free Report)

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.